TNF Inhibitors Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

TNF Inhibitors Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The TNF Inhibitors Market studied was anticipated to grow with a CAGR of nearly 9.5%, during the forecast period (2022-2027).

COVID-19 had an unprecedented impact on the growth of the market due to disruption in the supply chain across the globe. TNF inhibitors found large applications in the treatment of COVID-19 and expected to had a positive impact. For instance, the Journal of American Medical Association article titled "Association Between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death Among Patients With Immune-Mediated Inflammatory Disease and COVID-19" published in October 2021 concluded that TNF inhibitor monotherapy was associated with a lower risk of adverse COVID-19 outcomes compared with other commonly prescribed immunomodulatory treatment regimens among individuals with immune-mediated inflammatory diseases. Thus, studies that demonstrate the effectiveness of the TNF monotherapy treatment in COVID-19 patients were also expected to propel the growth of the market over the forecast period.

The major factors attributing to the growth of the market are the rise in the global prevalence of autoimmune disorders such as (RA) Rheumatoid Arthritis, Inflammatory Bowel Disorder, Psoriasis, and Crohn’s disease coupled with the increase in the aged population. For Instance, As per the 2021 International Foundation For Gastrointestinal Disorders (IFFGD), 10 to 15% of the population is affected by irritable bowel syndrome, worldwide, including 25 to 45 million people afflicted with the disease in the united states. As Crohn’s disease is a type of irritable bowel syndrome increasing the burden of it also boosts the growth of the market.

Furthermore, the approval of the products by the regulatory authorities also contributes to the growth of the market. For Instance, in December 2021, Coherus BioSciences, Inc. received United States Food and Drug Administration (FDA) approval for YUSIMRY (adalimumab-aqvh), formerly CHS-1420, a Humira (adalimumab) biosimilar product. YUSIMRY is indicated for plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, Crohn’s disease, and ulcerative colitis. Such approvals are propelling the growth of the studied market.

Thus, owing to the abovementioned factors, the market is anticipated to project growth over the forecast period. However, the high risk of complications, such as heart failure, liver injury, neurological disorders, psoriasis, and allergic reactions coupled with challenges while in the development stage and expensive patented biologics may hinder the growth of the market.

Key Market TrendsRheumatoid Arthritis Segment Is Expected to Project Large Growth Over the Forecast Period

Rheumatoid arthritis (RA) is an autoimmune condition in which the healthy tissues of the body are attacked by the immune system of the own body. Biologic drugs work by targeting proteins called cytokines, which are responsible for the inflammation caused by the immune system’s response. In the case of ‘anti-TNF’ drugs, the cytokines being targeted are called ‘TNF’ (TumourNecrosis Factor alpha). The factors such as the growing burden of diseases, approval of drugs by the regulatory authority, and the launch of products by the market players are propelling the growth of the market segment over the forecast period.

The growing burden of rheumatoid arthritis is largely propelling the growth of the market segment. For Instance, According to the World Health Organization, an update on Musculoskeletal conditions in February 2021, there is around 14 million rheumatoid arthritis in the world. Such a high prevalence of rheumatoid arthritis is also boosting the growth of the studied market.

Additionally, the approval of drugs by different regulatory authorities of the region and the launch of products is bolstering the growth of the market. For Instance, in March 2021, Samsung Bioepis launched its adalimumab biosimilar Hadlima in Australia in partnership with Merck & Co. Hadlima is approved for the treatment of rheumatoid arthritis and other indications in Australia. Such launch of TNF inhibitors for the treatment of rheumatoid arthritis is propelling the growth of the market segment.

Thus, owing to the abovementioned factors, the market segment is expected to project significant growth over the forecast period.

North America Dominates the Market and Expected to do Same Over the Forecast Period.

North America is expected to dominate the overall TNF inhibitors market throughout the forecast period. The dominance is due to several factors such as well-established direct reimbursement policies and the availability of advanced healthcare infrastructure in the region.

The growing burden of autoimmune diseases in different countries around the world is also propelling the growth of the market. For instance, in November 2020, the Autoimmune Registry Inc released its comprehensive list of autoimmune diseases in the United States which includes over 150 diseases, 40 subtypes, and 60 synonyms. It also reported that there are about 15 to 30 million people in the United States suffer from autoimmune disease, making it one of the nation's largest classes of illness, often affecting women between 20 and 40 years old. Such a high burden of disease in the nation is driving the growth of the market.

Also, the accelerating approval procedure of the United States Food and Drug Administration is propelling the growth in the region. For Instance, in February 2022, Pfizer Inc. received United States Food and Drug Administration (FDA) acceptance for review of the Prior Approval Supplement (PAS) to the Biologics License Application (BLA) for ABRILADA (adalimumab-afzb) as an interchangeable biosimilar to Humira (adalimumab).

Thus, owing to the abovementioned factors, the North American region is expected to show lucrative growth over the forecast period.

Competitive Landscape

The TNF inhibitors market is moderately competitive and consists of several major players. In terms of market share, few of the major players are currently dominating the market. Some prominent players are acquiring other companies to consolidate their market positions across the globe and while others are launching new products. Some of the companies which are currently dominating the market are Abbvie Inc, Pfizer Inc, Johnson & Johnson, Amgen Inc, and UCB Inc.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

Please note: This publisher does offer titles that are created upon receipt of order. If you are purchasing a PDF Email Delivery option above, the report will take approximately 2 business days to prepare and deliver.